The estimated Net Worth of James Hollingshead is at least $28.5 Million dollars as of 28 August 2023. Dr Hollingshead owns over 5,550 units of Resmed stock worth over $8,644,047 and over the last 12 years he sold RMD stock worth over $18,414,957. In addition, he makes $1,426,626 as Pres of Sleep & Respiratory Care Bus. at Resmed.
Dr has made over 71 trades of the Resmed stock since 2013, according to the Form 4 filled with the SEC. Most recently he bought 5,550 units of RMD stock worth $1,006,826 on 28 August 2023.
The largest trade he's ever made was exercising 22,903 units of Resmed stock on 11 November 2014 worth over $1,171,488. On average, Dr trades about 2,216 units every 32 days since 2013. As of 28 August 2023 he still owns at least 34,177 units of Resmed stock.
You can see the complete history of Dr Hollingshead stock trades at the bottom of the page.
Dr. James R. Hollingshead Ph.D. is the Pres of Sleep & Respiratory Care Bus. at Resmed.
As the Pres of Sleep & Respiratory Care Bus. of Resmed, the total compensation of Dr D at Resmed is $1,426,626. There are 9 executives at Resmed getting paid more, with Michael Farrell having the highest compensation of $10,429,800.
Dr D is 58, he's been the Pres of Sleep & Respiratory Care Bus. of Resmed since . There are 11 older and 11 younger executives at Resmed. The oldest executive at Resmed Inc. is Dr. Peter C. Farrell A.M., AM, B.E., BE (Hons), Ph.D., ScD, 79, who is the Founder & Non-Exec. Chairman.
James's mailing address filed with the SEC is C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON, MA, 01720.
Over the last 23 years, insiders at Resmed have traded over $250,830,262 worth of Resmed stock and bought 10,000 units worth $424,500 . The most active insiders traders include Peter C Farrell, Gary W Pace, and David Pendarvis. On average, Resmed executives and independent directors trade stock every 7 days with the average trade being worth of $3,005,701. The most recent stock trade was executed by Brett Sandercock on 9 September 2024, trading 1,000 units of RMD stock currently worth $246,420.
at resmed (nyse: rmd, asx: rmd) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. our cloud-connected medical devices transform care for people with sleep apnea, copd and other chronic diseases. our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. by enabling better care, we improve quality of life, reduce the impact of chronic disease and lower costs for consumers and healthcare systems in more than 120 countries.
Resmed executives and other stock owners filed with the SEC include: